Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NO_LONGER_AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this program is to see if giving convalescent plasma to individuals who test positive for COVID-19 may reduce their symptoms and help minimize complications from the illness.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019)

NCT04554992

Covid19

UNKNOWN PHASE1

Convalescent Plasma for the Treatment of COVID-19

NCT04389710

COVID-19

COMPLETED PHASE2

Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients

NCT04420988

COVID-19 SARS-CoV 2 SARS-CoV Infection

NO_LONGER_AVAILABLE

Use of Convalescent Plasma for COVID-19

NCT04408040

COVID

TERMINATED PHASE2

COVID-19 Convalescent Plasma for Mechanically Ventilated Population

NCT04388527

Covid-19

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

As individuals are exposed to pathogens, the body's immune system works to create antibodies toward those pathogens. These antibodies can be found in the plasma portion of the blood. This plasma is referred to as "Convalescent plasma" and contains these infection fighting antibodies. Through a blood donation, this convalescent plasma is collected from a recovered person and transfused to a sick patient who is still fighting the same virus. This protocol will make convalescent COVID-19 plasma available to individuals who meet the eligibility criteria described.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID Sars-CoV2 Corona Virus Infection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Convalescent Plasma

One to two 200 mL units of Convalescent plasma per infusion, up to 6 total units within a 3-week period.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* At least 12 years of age
* Covid-19 Convalescent Plasma (CCP) treatment is in line with the patient's current goals of care (i.e. recipient cannot be DNI status)
* Laboratory confirmed diagnosis of infection with SARS-CoV-2 that is severe or life threatening OR the individual is judged by the treating provider to be at a high risk of progression to severe or life-threatening disease.
* Severe COVID-19 is defined by one or more of the following:

1. Dyspnea
2. Respiratory frequency ≥ 30/min
3. Blood oxygen saturation ≤ 93%
4. Partial pressure of arterial oxygen to fraction of inspired oxygen ratio \< 300
5. Lung infiltrates \> 50% within 24-48 hours
* Life-threatening COVID-19 is defined as one or more of the following:

1. Respiratory failure
2. Septic shock
3. Multiple organ dysfunction or failure